Drug Information

Drug General Information
Drug ID
D0G6QF
Former ID
DCL000350
Drug Name
Vandetanib
Synonyms
Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Approved [531783], [541055]
Therapeutic Class
Anticancer Agents
Company
AstraZeneca
Structure
Download
2D MOL

3D MOL
Formula
C22H24BrFN4O2
InChI
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
InChIKey
UHTHHESEBZOYNR-UHFFFAOYSA-N
CAS Number
CAS 443913-73-3
PubChem Compound ID
3081361
PubChem Substance ID
8030012, 8034317, 9471114, 12015522, 14716916, 14761077, 36412170, 46394288, 47208064, 49742597, 50068212, 50100123, 50112766, 50599279, 53789193, 57354678, 85246147, 91147360, 92721418, 93309619, 93581029, 93692935, 99436956, 99445235, 103194628, 103905338, 111682639, 123110212, 124756961, 124772087, 124893337, 124893338, 125163767, 125350704, 126619162, 126651857, 126661732, 126731545, 127330006, 127330007, 131333378, 131408693, 134339002, 134964431, 135228305, 135685324, 135685325, 135685344, 135697656, 135727395
ChEBI ID
ChEBI:49960
SuperDrug ATC ID
L01XE12
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 2 Target Info Inhibitor [536474], [550288]
Proto-oncogene tyrosine-protein kinase receptor ret Target Info Inhibitor [536474], [550288]
Epidermal growth factor receptor Target Info Inhibitor [536474], [550288]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancerhsa04144:Endocytosis
Pathways in cancer
Thyroid cancer
Central carbon metabolism in cancerhsa04010:MAPK signaling pathway
ErbB signaling pathway
Calcium signaling pathway
HIF-1 signaling pathway
FoxO signaling pathway
Dorso-ventral axis formation
Adherens junction
Gap junction
Regulation of actin cytoskeleton
GnRH signaling pathway
Estrogen signaling pathway
Oxytocin signaling pathway
Epithelial cell signaling in Helicobacter pylori infection
Hepatitis C
Proteoglycans in cancer
MicroRNAs in cancer
Pancreatic cancer
Endometrial cancer
Glioma
Prostate cancer
Melanoma
Bladder cancer
Non-small cell lung cancer
Central carbon metabolism in cancer
Choline metabolism in cancer
NetPath Pathway IL2 Signaling PathwayNetPath_16:IL4 Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathwayP00012:Cadherin signaling pathway
EGF receptor signaling pathway
Pathway Interaction Database HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networkret_pathway:Signaling events regulated by Ret tyrosine kinase
Posttranslational regulation of adherens junction stability and dissassemblylysophospholipid_pathway:LPA receptor mediated events
Signaling events mediated by PTP1B
Arf6 signaling events
Thromboxane A2 receptor signaling
Regulation of Telomerase
EGF receptor (ErbB1) signaling pathway
EGFR-dependent Endothelin signaling events
Posttranslational regulation of adherens junction stability and dissassembly
Direct p53 effectors
ErbB1 downstream signaling
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
E-cadherin signaling in keratinocytes
ErbB receptor signaling network
Internalization of ErbB1
Stabilization and expansion of the E-cadherin adherens junction
a6b1 and a6b4 Integrin signaling
Syndecan-3-mediated signaling events
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
SHC1 events in ERBB2 signaling
PLCG1 events in ERBB2 signaling
PIP3 activates AKT signaling
GRB2 events in EGFR signaling
GAB1 signalosome
SHC1 events in EGFR signaling
EGFR downregulation
GRB2 events in ERBB2 signaling
PI3K events in ERBB2 signaling
EGFR Transactivation by Gastrin
Constitutive Signaling by Aberrant PI3K in Cancer
Constitutive Signaling by EGFRvIII
RAF/MAP kinase cascade
WikiPathways Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
AngiogenesisWP706:SIDS Susceptibility Pathways
Dopaminergic NeurogenesisWP673:ErbB Signaling Pathway
Regulation of Actin Cytoskeleton
EGF/EGFR Signaling Pathway
MAPK Signaling Pathway
Aryl Hydrocarbon Receptor Pathway
Extracellular vesicle-mediated signaling in recipient cells
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Bladder Cancer
Hair Follicle Development: Induction (Part 1 of 3)
Signaling by ERBB4
Signaling by ERBB2
Gastrin-CREB signalling pathway via PKC and MAPK
PIP3 activates AKT signaling
Nanoparticle-mediated activation of receptor signaling
Aryl Hydrocarbon Receptor
Spinal Cord Injury
Integrated Pancreatic Cancer Pathway
Gastric cancer network 2
AGE/RAGE pathway
Signaling Pathways in Glioblastoma
Arylhydrocarbon receptor (AhR) signaling pathway
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
Integrated Breast Cancer Pathway
Signaling by EGFR
L1CAM interactions
References
Ref 5317832011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
Ref 541055(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
Ref 536474A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.